0000000000627730

AUTHOR

Siamak Daneshmand

showing 3 related works from this author

Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival

2016

Background Renal cell carcinoma forming a venous tumor thrombus (VTT) in the inferior vena cava (IVC) has a poor prognosis. Recent investigations have been focused on prognostic markers of survival. Thrombus consistency (TC) has been proposed to be of significant value but yet there are conflicting data. The aim of this study is to test the effect of IVC VTT consistency on cancer specific survival (CSS) in a multi-institutional cohort. Methods The records of 413 patients collected by the International Renal Cell Carcinoma–Venous Thrombus Consortium were retrospectively analyzed. All patients underwent radical nephrectomy and tumor thrombectomy. Kaplan–Meier estimate and Cox regression analy…

medicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatment030232 urology & nephrologyRetrospective cohort studyGeneral Medicinemedicine.diseaseInferior vena cavaNephrectomy03 medical and health sciences0302 clinical medicineOncologymedicine.veinRenal cell carcinoma030220 oncology & carcinogenesismedicineSurgeryRadiologyThrombusStage (cooking)businessSurvival analysisJournal of Surgical Oncology
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

ASSOCIATION OF AN ORGAN TRANSPLANT-BASED APPROACH WITH A DRAMATIC REDUCTION IN POSTOPERATIVE COMPLICATIONS FOLLOWING RADICAL NEPHRECTOMY AND TUMOR TH…

2019

Objectives: Our aim was to determine whether using an organ transplant-based(TB) approach reduces postoperative complications(PCs) following radical nephrectomy(RN) and tumor thrombectomy(TT) in renal cell carcinoma(RCC) patients with level II-IV thrombi. Methods: A total of 390(292 non-TB/98 TB) IRCC-VT Consortium patients who received no preoperative embolization/IVC filter were included. Stepwise linear/logistic regression analyses were performed to determine significant multivariable predictors of intraoperative estimated blood loss(IEBL), number blood transfusions received, and overall/major PC development within 30days following surgery. Propensity to receive the TB approach was contr…

MaleKidney DiseaseVena Cavamedicine.medical_treatment030232 urology & nephrologyLogistic regressionNephrectomyOrgan transplantation0302 clinical medicinePostoperative ComplicationsRenal cell carcinomaInferior vena cavaCancerThrombectomyGeneral MedicineMiddle AgedNephrectomyRenal cell carcinomaKidney NeoplasmsOncologymedicine.vein030220 oncology & carcinogenesisFemaleInferior vena cava; Postoperative complications; Renal cell carcinoma; Surgical technique; Tumor thrombus6.4 SurgeryInferiormedicine.medical_specialtyOncology and CarcinogenesisUrologyIvc filterVena Cava InferiorInferior vena cavaArticle03 medical and health sciencesPostoperative complicationsRare DiseasesBlood lossmedicineHumansBlood TransfusionOncology & CarcinogenesisCarcinoma Renal CellRetrospective Studiesbusiness.industryCarcinomaRenal CellEvaluation of treatments and therapeutic interventionsSurgical techniqueThrombosismedicine.diseasePostoperative complicationTumor thrombusPropensity score matchingSurgerybusinessFollow-Up Studies
researchProduct